Literature DB >> 8864519

Modulation by atrial natriuretic factor of receptor-mediated cyclic AMP-dependent responses in canine pulmonary artery during heart failure.

R Mathew1, H A Omar, R Fayngersh, W Shen, J Wang, M H Gewitz, T H Hintze, M S Wolin.   

Abstract

1. Pacing-induced congestive heart failure (CHF) in dogs is associated with increased plasma levels of atrial natriuretic factor (ANF) and inhibition of receptor-mediated cyclic AMP-dependent relaxation in isolated pulmonary arteries (PA). Since ANF is known to be negatively coupled to adenylate cyclase, we studied cyclic AMP-mediated relaxation to isoprenaline (Iso) and arachidonic acid (AA) in PA from control dogs (C), dogs with pacing-induced CHF (CHF) and dogs with bilateral atrial appendectomy and CHF (ATR APP+CHF). 2. In CHF, plasma ANF levels increased from a baseline of 80 +/- 8 pg ml-1 to 283 +/- 64 pg ml-1 (P < 0.05), but the ATR APP+CHF group failed to show this increase (67 +/- 7 pg ml-1 vs 94 +/- 15 pg ml-1, P = NS). Plasma ANF levels, however, did not influence myocardial dysfunction in CHF. 3. The relaxation of 49 +/- 5% to 1 microM Iso in C was reduced to 23 +/- 4% in CHF (P < 0.05), but relaxation of 49 +/- 12% was observed in the ATR APP+CHF group (P = NS vs C). Relaxation responses to 10 microM AA were as follows: 77 +/- 5% (C, n = 8), 27 +/- 8% (CHF, n = 10, P < 0.05 vs C), and 93 +/- 5% (ATR APP+CHF, n = 5). The presence of CHF, or the plasma ANF levels, did not affect responses to cyclic GMP-mediated relaxing agents in PA. 4. These data indicate that the myocardial performance in CHF is not influenced by plasma ANF levels. However, altered cyclic AMP-mediated relaxation in PA during CHF is, in part, modulated by circulating ANF levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864519      PMCID: PMC1909859          DOI: 10.1111/j.1476-5381.1996.tb15620.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Atrial wall function and plasma atriopeptin during volume expansion in conscious dogs.

Authors:  T H Hintze; J J McIntyre; M B Patel; J T Shapiro; M DeLeonardis; G A Zeballos; A V Loud
Journal:  Am J Physiol       Date:  1989-03

2.  Physiological role of silent receptors of atrial natriuretic factor.

Authors:  T Maack; M Suzuki; F A Almeida; D Nussenzveig; R M Scarborough; G A McEnroe; J A Lewicki
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

3.  Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor.

Authors:  B S Edwards; R S Zimmerman; T R Schwab; D M Heublein; J C Burnett
Journal:  Circ Res       Date:  1988-02       Impact factor: 17.367

4.  Arachidonic acid metabolites and endothelial injury: studies with cultures of human endothelial cells.

Authors:  A R Johnson; G Revtyak; W B Campbell
Journal:  Fed Proc       Date:  1985-01

5.  Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia.

Authors:  V J Dzau; M Packer; L S Lilly; S L Swartz; N K Hollenberg; G H Williams
Journal:  N Engl J Med       Date:  1984-02-09       Impact factor: 91.245

6.  Atrial natriuretic factor: a hormone produced by the heart.

Authors:  A J de Bold
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

7.  Atrial natriuretic peptide elevation in congestive heart failure in the human.

Authors:  J C Burnett; P C Kao; D C Hu; D W Heser; D Heublein; J P Granger; T J Opgenorth; G S Reeder
Journal:  Science       Date:  1986-03-07       Impact factor: 47.728

8.  Atrial natriuretic factor partially inhibits the stimulated catecholamine synthesis in superior cervical ganglia of the rat.

Authors:  W Debinski; O Kuchel; N T Buu; M Cantin; J Genest
Journal:  Neurosci Lett       Date:  1987-06-01       Impact factor: 3.046

9.  Atrial natriuretic factor reduces cyclic adenosine monophosphate content of human fibroblasts by enhancing phosphodiesterase activity.

Authors:  M A Lee; R E West; J Moss
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

10.  Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart.

Authors:  A M Feldman; A E Cates; W B Veazey; R E Hershberger; M R Bristow; K L Baughman; W A Baumgartner; C Van Dop
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.